| 51 |
23463968 | Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure. | 2013 Mar |
1 |
| 52 |
23743487 | Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. | 2013 Jun |
2 |
| 53 |
23858000 | Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. | 2013 Dec |
1 |
| 54 |
24095030 | Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). | 2013 Dec 1 |
1 |
| 55 |
21607553 | Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients. | 2012 Jun |
1 |
| 56 |
22027579 | Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. | 2012 Mar |
1 |
| 57 |
22111754 | Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. | 2012 |
2 |
| 58 |
22323742 | Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug. | 2012 May |
1 |
| 59 |
22357577 | Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. | 2012 Mar |
1 |
| 60 |
22437213 | Hyponatremia, heart failure, and the role of tolvaptan. | 2012 Mar |
1 |
| 61 |
22917555 | Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). | 2012 Dec 1 |
1 |
| 62 |
22971027 | Update on tolvaptan for the treatment of hyponatremia. | 2012 Aug |
1 |
| 63 |
22999071 | Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). | 2012 Dec 15 |
1 |
| 64 |
23051949 | Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. | 2012 Nov |
1 |
| 65 |
23068288 | Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. | 2012 Dec |
1 |
| 66 |
21641352 | Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. | 2011 Jun |
1 |
| 67 |
21694950 | Tolvaptan, hyponatremia, and heart failure. | 2011 |
1 |
| 68 |
21816754 | Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. | 2011 Nov |
1 |
| 69 |
21881396 | Hyponatremia in hospitalized patients: the potential role of tolvaptan. | 2011 Aug |
1 |
| 70 |
20197265 | Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. | 2010 Apr |
1 |
| 71 |
20435194 | Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. | 2010 May |
3 |
| 72 |
20467590 | Tolvaptan for the treatment of hyponatremia and congestive heart failure. | 2010 Mar |
1 |
| 73 |
20508668 | Hyponatremia: Prolonged use of the vasopressin antagonist tolvaptan is a safe and effective treatment for hyponatremia. | 2010 Jun |
1 |
| 74 |
20608824 | Vasopressin-receptor antagonists. | 2010 Jul |
1 |
| 75 |
20708094 | Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. | 2010 Oct |
1 |
| 76 |
20926941 | Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan. | 2010 Nov-Dec |
1 |
| 77 |
21104220 | [Treatment of hyponatremia: role of vaptans]. | 2010 Dec |
1 |
| 78 |
21180368 | Tolvaptan: any evidence of efficacy in SIADH? | 2010 Oct |
1 |
| 79 |
22111741 | Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia. | 2010 Sep |
2 |
| 80 |
19092365 | Vasopressin and vasopressin receptor antagonists in heart failure. | 2009 Jan-Feb |
1 |
| 81 |
18306096 | Hyponatremia in psychiatric patients: update on evaluation and management. | 2008 |
1 |
| 82 |
18510477 | Role of tolvaptan in acute decompensated heart failure. | 2008 Jun |
1 |
| 83 |
18544725 | Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. | 2008 Jun 11 |
1 |
| 84 |
18992654 | Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. | 2008 Nov 11 |
1 |
| 85 |
19018685 | EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan. | 2008 Nov |
3 |
| 86 |
20694082 | Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. | 2008 Jun |
1 |
| 87 |
17384438 | Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. | 2007 Mar 28 |
1 |
| 88 |
17657988 | [Recent progress in vasopressin research on cardiovascular diseases]. | 2007 Jun |
1 |
| 89 |
17703139 | Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. | 2007 Aug |
1 |
| 90 |
16634691 | Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. | 2006 May |
1 |
| 91 |
16794787 | Vasopressin antagonists. | 2006 Aug |
1 |
| 92 |
19804253 | Tolvaptan for the treatment of hyponatremia and congestive heart failure. | 2006 Nov |
1 |
| 93 |
15695526 | Vasopressin antagonism: a future treatment option in heart failure. | 2005 Mar |
1 |
| 94 |
15880334 | Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). | 2005 May |
4 |
| 95 |
15926866 | Vasopressin receptor antagonists in the management of acute heart failure. | 2005 May |
1 |
| 96 |
15926874 | The therapeutic potential of vasopressin receptor antagonists in congestive heart failure. | 2005 May |
1 |
| 97 |
15113814 | Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. | 2004 Apr 28 |
2 |
| 98 |
15461553 | Is vasopressin-receptor antagonism an advancement in the treatment of heart failure? | 2004 Oct |
1 |